Institute for Liver and Digestive Diseases, Hallym University College of Medicine, Chuncheon 24253, Korea.
Int J Mol Sci. 2020 Dec 28;22(1):199. doi: 10.3390/ijms22010199.
Liver cirrhosis is one of the most prevalent chronic liver diseases worldwide. In addition to viral hepatitis, diseases such as steatohepatitis, autoimmune hepatitis, sclerosing cholangitis and Wilson's disease can also lead to cirrhosis. Moreover, alcohol can cause cirrhosis on its own and exacerbate chronic liver disease of other causes. The treatment of cirrhosis can be divided into addressing the cause of cirrhosis and reversing liver fibrosis. To this date, there is still no clear consensus on the treatment of cirrhosis. Recently, there has been a lot of interest in potential treatments that modulate the gut microbiota and gut-liver axis for the treatment of cirrhosis. According to recent studies, modulation of the gut microbiome by probiotics ameliorates the progression of liver disease. The precise mechanism for relieving cirrhosis via gut microbial modulation has not been identified. This paper summarizes the role and effects of the gut microbiome in cirrhosis based on experimental and clinical studies on absorbable antibiotics, probiotics, prebiotics, and synbiotics. Moreover, it provides evidence of a relationship between the gut microbiome and liver fibrosis.
肝硬化是全球最常见的慢性肝脏疾病之一。除了病毒性肝炎,脂肪性肝炎、自身免疫性肝炎、硬化性胆管炎和威尔逊病等疾病也可导致肝硬化。此外,酒精本身可导致肝硬化,并可加重其他病因的慢性肝病。肝硬化的治疗可分为针对肝硬化病因和逆转肝纤维化。迄今为止,对于肝硬化的治疗仍未达成明确共识。最近,人们对调节肠道微生物群和肠道-肝脏轴以治疗肝硬化的潜在治疗方法产生了浓厚的兴趣。根据最近的研究,益生菌对肠道微生物群的调节可改善肝病的进展。通过肠道微生物调节缓解肝硬化的确切机制尚未确定。本文基于对可吸收抗生素、益生菌、益生元和合生元的实验和临床研究,总结了肠道微生物群在肝硬化中的作用和影响。此外,本文还提供了肠道微生物群与肝纤维化之间关系的证据。